Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® NeuroTech Attends 15th CFCVD


Beijing, China – From April 12 to April 15, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") attended the 15th China Forum of Cerebrovascular Diseases ("CFCVD") held in Beijing. The CFCVD is one of the most premier academic events in China's cerebrovascular diseases field, covering intracranial stent, arterial aneurysm, AVM, carotid artery lesion, thrombectomy, severe case treatment, nursing, and other interventional and surgical treatment of cerebrovascular diseases.
In the session of arterial aneurysm, Professor Xiaodong Xie of West China Hospital of Sichuan University gave a presentation on safety and efficacy of WILLIS® Intracranial Stent Graft System ("WILLIS®"). Researched and developed independently by MicroPort® NeuroTech, WILLIS® is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China, and also the first medical device to achieve complete vascular reconstruction in China. WILLIS® vascular reconstruction achieves complete occlusion, and unlike traditional treatment using stent-assisted coil embolization, WILLIS® effectively shunts the blood flow and keeps it off of the aneurysm wall. Based on his clinical cases in West China Hospital, Professor Xie spoke highly of the excellent performance of WILLIS®, and had active interaction with experts in attendance regarding their clinical experience with WILLIS®.
MicroPort® NeuroTech also displayed its innovative product - Tubridge® Vascular Reconstruction Device ("Tubridge®"), that was newly granted the approval from China Food and Drug Administration ("CFDA"), which attracted a lot of attendees to inquire for product information. Tubridge® is the first China-developed intracranial stent with densely meshed wire braids. It is designed for the treatment of large and giant cerebral aneurysm. The device cures the cerebral aneurysm by effectively diverting the blood flow based on the hemodynamics, reducing the impact of blood flow to the cerebral aneurysm, and enabling the endothelial cells to grow along the stent struts and gradually repair aneurysmal neck. The clinical performance of Tubridge® gained high recognition from experts in attendance and they expressed their expectation on its future clinical application.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® CardioFlow Attends Fourth China Valve (Hangzhou) Meeting
[Next]:MicroPort® Orthopedics Holds China-Australia Medial Pivot Knee Seminar